Staar Surgical Company · NASDAQ:STAA
Staar Surgical — Investor Day (2019)
26 slides from Staar Surgical's investor day presentation, 2019
Slide 1: STAAR Surgical
STAAR Surgical Evolution in Visual Freedom™ “D> STAARSURGICAL”
Slide 2: Forward Looking Statements
Forward Looking Statements Evolution in Visual Freedom™ >STAARSURGICAL All statements in this presentation that are not statements of historical fact are forward-looking statements, including statements about the Ophthalmic industry, our business and financial results including any of the following:
Slide 3: The Future of Refractive Surgery is Lens-Based...
The Future of Refractive Surgery is Lens-Based... Evolution in Visual Freedom™ “2 STAARSURGICAL “Intraocular refractive surgery is the next wave of growth in the eyecare space and STAAR is the clear leader in this technology. The success that STAAR has demonstrated in Asia is a leading indicator for
Slide 4: Proprietary Lens Technology and Business Model is Driving Industry-Leading Growth
“]D STAARSURGICAL” The Future of Refractive Surgery is Lens-Based... Proprietary Lens Technology and Business Model is Driving Industry-Leading Growth Strong Financial Performance includes Expanding Margins and Cash Generation Evolution in Visual Freedom™
Slide 5: STAAR is Targeting Distance Vision and Near Vision: Two Large Markets
STAARSURGICAL STAAR is Targeting Distance Vision / Nearsightedness Near Vision / Reading Glasses Two Large Markets Evolution in Visual Freedom™
Slide 6: Number of Myopes
6000 60% 5000 50% 4000 40% 3000 30% 2000 20% 1000 10% 0 0% 2000 2010 2020 2030 2040 2050 Number of Myopes Myopia prevalence (%)
Slide 7: 99.4% of Patients Would Elect STAAR's EVO ICL Again
STAARSURGICAL Proprietary 99.4% of Patients Lens-Based Would Elect STAAR’s EVO Implantable Collamer® Lens Again* Technology Over 1 Million ICLs™ Implanted Globally Evo Evolution in Visual Freedom™
Slide 8: Proprietary Lens-Based Technology
Proprietary Lens-Based Technology Natural Crystalline Lens lris Cornea Evolution in Visual Freedom™ STAARSURGICAL ICL Advantages Bio- No Dry Eye Removeable — Eco-Friendly Compatible Syndrome Upgradeable Proprietary No Capital a aves Collamer Additive Material Excellent UV Quiet in Night Vision Prote
Slide 9: Quarterly Growth Trend
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4E
Slide 10: ICL Sales by Country
Japan China Korea TOTAL* UAE Malaysia Italy UK Russia Colombia Germany
Slide 11: Annual Results 2015-2019 YTD
• 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 YTD YTD* • 2015 2016 2017 2018 2018 YTD* 2019 YTD*
Slide 12: Results 2015-2019 YTD
• 2015 2016 2017 2018 2019 YTD* • 2015 2016 2017 2018 9/28/2019
Slide 13: STAAR's Global Eyeprint
STAAR’s Global “Eyeprint” Ra Evolution in Visual Freedom™ STAARSURGICAL 75 Countries Globally Direct Markets: United States | Canada| U.K. | Germany | Spain | Japan| 3
Slide 14: ICL Global Market Share
ICL Global Market Share* Evolution in Visual Freedom™ STAARSURGICAL From < 2% to 6% Other APAC ; 2% LATAM US. India 1% 1% 4% DistOps Canada 1% Germany. 5% 4
Slide 15: EVO Has Captured 14% Market Share
STAARSURGICAL EVO Has Captured 14% Market Share* Peak Summer Season = Thousands of ICLs Daily Hospital Waiting Room Surgeon WeChat Posting of EVO Patients Evolution in Visual Freedom™ 15
Slide 16: Consumer Marketing and EVO Only Clinics Propels EVO Growth
“D STAARSURGICAL Consumer Marketing EVO Only Clinics Propels EVO Growth Paradigm Change 0, ESF, RES ARRALT Ae Evolution in Visual Freedom™
Slide 17: Japan
Japan The Japanese Ophthalmological Society modified its surgical indication criteria for recommended use of phakic intraocular lenses, such as the EVO Visian ICL, from -6.0 diopters to -3.0 diopters in 2019. Evolution in Visual Freedom™ STAARSURGICAL Surgeon Support + Consumer Marketing + Celebrity
Slide 18: Germany and Spain
STAARSURGICAL Germany Surgeon Support + Strategic Partnerships and Spain The German refractive society expanded recommended range for use of phakic refractive lenses, including EVO from -6.0D to -3.0D* in 2019. Strategic Partnerships 49 eye clinics spanning Spain, France, Portugal and Morocco 13 eye
Slide 19: United States
United States Evolution in Visual Freedom™ STAARSURGICAL Bring Successful OUS Business Model to U.S. Visian Toric ICL approval returned U.S. to growth in Q4’'18 EVO Visian ICL Clinical Trial Imminent Inaugural U.S. Surgeons Council Summit (Dallas) Bringing OUS business model of premium and primary I
Slide 20: Visian ICL
Evolution in Visual Freedom™ “<2 STAARSURGICAL” “> Visian|ICL® 20
Slide 21: STAAR's Execution: Three-Year Financial Outlook
STAAR’s Execution Three-Year Financial Outlook Provided at and Execution... Evolution in Visual Freedom™ STAARSURGICAL Promises Made. Promises Kept. Outlook 2018 - 2020 | | Execution 2018 + 2019 YTD* Annual Revenue Growth of 15 - 20% - 37% Annual Revenue 20% Growth Stretch Annual ICL Unit Growth of
Slide 22: STAAR's Vision: Strategic Imperatives
STAAR’s Vision Strategic Imperatives Evolution in Visual Freedom™ STAARSURGICAL We have a Passionate Commitment to Deliver Visual Freedom to Patients for an Active and Fulfilling Life Independent of Contact Lenses and Glasses... Position EVO Implantable Lenses as a Special and Transformational Pathw
Slide 23: Financial Outlook
Financial Outlook Fiscal Year 2020 Emphasis: Evolution in Visual Freedom™ (e) op REVENUE GROWTH ICL UNIT GROWTH PROFITABILITY IMPROVEMENT STAARSURGICAL Profitability Improves balanced by Prudent Investment Consumer Awareness Commercialization Clinical Studies CASH FLOW AND BALANCE SHEET Strong Cash
Slide 24: 2020-2022 Revenue
2020-2022 Evolution in Visual Freedom™ “D STAARSURGICAL REVENUE EDOF Presbyopia ICL on market in Q2 2020 followed by phased rollout US growth accelerates, preparing key cities for future EVO launch Keep building China, aiming for 25%+ procedure share Continue modest trade-offs of price for volume in
Slide 25: 2020-2022 Unit Costs
2020-2022 Evolution in Visual Freedom™ “D STAARSURGICAL UNIT COSTS * Target $1.5M Reduction in Manufacturing Costs Annually in planning cycle OPERATING EXPENSES * Overall Spending Growth Slows in Latter Part of Planning Period * R&D Spend as a Percentage of Sales Settles into the Mid-Teens by the en
Slide 26: The Future of Refractive Surgery is Lens-Based...
The Future of Refractive Surgery is Lens-Based... Evolution in Visual Freedom™ “D> STAARSURGICAL”